Sign up
Pharma Capital

Scancell inks research collaboration deal with European biopharma BioNTech

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors
cancer cells under a microscope
BioNTech recently raised US$270mln as part of a Series A funding

Cancer immunotherapy specialist Scancell Holdings Plc (LON:SCLP) has entered into a research collaboration agreement with European biopharma BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer.

The research collaboration will combine Scancell’s Moditope immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T-cell receptors.

READ: Scancell soars as it confirms Cancer Research UK to fund and sponsor SCIB2 clinical trial

Moditope is a new class of potentially potent immunotherapy agents which stimulate the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

To get a bit scientific, Moditope stimulates the production of the CD4+ T cells using tumour-associated peptide epitopes which allow the activated T cells to seek out and kill tumour cells that would otherwise have been hidden from the immune system.

Once the initial studies have been completed, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Scancell’s Modi-1 epitopes.

‘Great potential’

“We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer,” Scancell’s chief scientific officer Lindy Durrant.

READ: Scancell on the lookout for partners after year of “significant progress”

“Pre-clinical data from our Moditope platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition.

“We believe that this, combined with BioNTech's engineered T cells specific to Moditope epitopes, could have great potential as a novel immunotherapy.”

View full SCLP profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.